Menu

Dr. Reddy's Laboratories

Overview

Dr. Reddy's Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana. Founded in 1984 by Kallam Anji Reddy, the company is engaged in the manufacture and marketing of a wide range of pharmaceuticals in India and overseas, including active pharmaceutical ingredients (APIs), generic medicines, branded formulations, biosimilars, and proprietary products. It is one of the largest pharmaceutical companies originating from India and is listed on the BSE, NSE, and the New York Stock Exchange.

Key Facts

Name Dr. Reddy's Laboratories Limited
Industry Pharmaceuticals
Founder Kallam Anji Reddy
Founded 1984
Headquarters Hyderabad, Telangana, India
Country India
Stock listings BSE, NSE, NYSE
Type Public company

Background

Dr. Reddy's was established by Kallam Anji Reddy, a chemical engineer who had earlier worked at the public sector firm Indian Drugs and Pharmaceuticals Limited (IDPL) and founded Standard Organics before starting Dr. Reddy's. The company began operations focused on the manufacture of bulk drugs (APIs) for domestic and export markets, before progressively integrating forward into branded formulations, generics, and research-led drug development.

The company operates manufacturing facilities and research centres in India and abroad, with significant business in the United States, Europe, Russia and the Commonwealth of Independent States (CIS), and emerging markets. Its business is broadly organised across Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products.

History and Timeline

  • 1984: Dr. Reddy's Laboratories founded in Hyderabad by Kallam Anji Reddy.
  • 1986: Made its initial public offering on Indian stock exchanges.
  • 1990s: Expanded into branded formulations and began exports of APIs to regulated markets.
  • 2001: Became the first Asia-Pacific pharmaceutical company outside Japan to list on the New York Stock Exchange.
  • 2006: Acquired the German generics company betapharm, marking a major step into the European generics market.
  • 2010s: Expanded biosimilars portfolio and proprietary product pipeline; faced regulatory scrutiny from the U.S. Food and Drug Administration on certain manufacturing facilities.
  • 2020: Partnered with the Russian Direct Investment Fund for the conduct of clinical trials and distribution of the Sputnik V COVID-19 vaccine in India.

Operations and Products

Dr. Reddy's portfolio spans therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. The company is among the leading Indian suppliers of generic medicines to the United States and is also active in over-the-counter products in select markets. Its biosimilars division has developed and commercialised products including a rituximab biosimilar, which was among the early biosimilars launched in India.

Leadership

The company was led by its founder Kallam Anji Reddy until his death in 2013. Members of the founding family have continued to play leading roles in governance and management, with G. V. Prasad and Satish Reddy holding senior leadership positions in subsequent years.

Significance

Dr. Reddy's is regarded as one of the pioneers of the Indian generics industry and among the early Indian pharmaceutical firms to invest substantially in research and development, including new chemical entity research. Its NYSE listing in 2001 was a landmark event for Indian pharmaceutical companies seeking access to global capital markets, and its acquisitions in Europe contributed to the global expansion of Indian pharma in the 2000s.

References